記事一覧

• Yoshimoto T, Hattori Y, Ishiyama H, Kiyoshige E, Ogata S, Nishimura K, Okada Y, Akaiwa Y, Kawamoto M, Ichijo M, Inoue H, Mizuno T, Tomimoto H, Kawakami D, Ihara M.
  Long-term outcomes in the pre-moyamoya stage of RNF213-related vasculopathy presenting with ischaemic stroke or transient ischaemic attack: insights from the NCVC Genome Registry
  Lancet Reg Health West Pac 2026; 70:101863.

• 越智雅之.
  サルコペニアとAGEs
  アンチ・エイジング医学 2026; 22:162-165.

• Nakashima I, Ohashi T, Yokoyama K, Kaida K, Nakahara J, Kondo T, Yoshikura N, Shimizu Y, Nohara C, Sakurai K, Yokote H, Niino M, Yamamura T, Fujihara K, Isobe N, Ochi H, Mori M, Kawachi I, Shimizu F, Kanda M, Tani Y, Fukazawa T
  A multicenter, retrospective study in patients with multiple sclerosis treated with natalizumab in a real-world setting in Japan: The REFIND study.
  Mult Scler Relat Disord 2026; 107:107007

• Fujihara K, Isobe N, Miyamoto K, Niino M, Nakahara J, Hattori S, Tanaka M, Tahara M, Suzumura A, Sakurai K, Yoshikura N, Shiomi K, Ochi H, Nagata E, Deguchi K, Tomizawa Y, Yamashita K, Nagatsuka T, Adachi H, Nakashima I
  Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study).
  Mult Scler 2026; 32:302-314.

• Ochi H, Nakamura S, Nakahara J
  B cell depletion as a therapeutic strategy for neuromyelitis optica spectrum disorder: rationale, evidence, and challenges.
  Front Immunol 2025; 16:1635989.

• Ochi H, Fukazawa T, Yamamura T, Yokoyama K, Ohashi T, Nakashima I, Mizuno M, Fukaura H, Kawauchi I, Okuno T, Sato R, Makioka H, Tsuchiya A, Kanda M, Sato Y, Saida T.
  Safety and effectiveness of dimethyl fumarate in Japanese patients with multiple sclerosis: 2-year post-marketing surveillance data.
  Neurol Clin Neurosci 2025; 14:54-68.

• Miura S, Suenaga S, Goto H, Wang Z, Makino A, Fan L, Senzaki K, Ochi M, Ohyagi Y, Shibata H.
  A Japanese patient with hereditary spastic paraplegia with a rare KIF5A nonsense variant.
  Hum Genome Var 2025; 12:11

• Okada Y, Tabara Y, Kohara K, Takei S, Ochi M, Igase M, Ohyagi Y.
  Morphologic variation of the circle of Willis is associated with cognitive impairment in a general population: The J-SHIPP study.
  J Stroke Cerebrovasc Dis 2025; 34:108287

• Matsui N, Tanaka K, Kokubun N, Hatanaka Y, Ishida M, Osaki Y, Watanabe T, Watanabe O, Matsuura E, Takashima H, Sato Y, Kuwabara S, Izumi Y.
  Japanese Isaacs study group (including Ochi M). Prevalence, clinical profiles, and prognosis of Isaacs syndrome: A nationwide survey study in Japan.
  J Neurol Sci 2025; 472:123442

• Nishigori R, Hamatani M, Yoshitomi H, Kimura K, Takata M, Ashida S, Fujii C, Ochi H, Takahashi R, Kondo T, Ueno H.
  CD21lo B-cell subsets are recruited to the central nervous system in acute neuromyelitis optica.
  Brain 2025; 148:2995-3010.

• 越智博文．
  多発性硬化症の症候学：シャルコーの3徴を越えて
  BRAIN and NERVE 2025; 77:1185-1193.

• 越智博文．
  多発性硬化症の現在地〜再発しない疾患への変貌〜
  愛媛医学 2025; 44:166-175.